Last edition
News about "gastric cancer"
US FDA Approves Phase III Trial of Cadonilimab Against Nivolumab in Gastric Cancer
The FDA’s clearance enables a global phase III study evaluating Cadonilimab, in combination with chemotherapy, as a first-line option for HER2-negative, unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma, directly comparing its efficacy to standard chemotherapy with or without Nivolumab.
Gastric Cancer | 12/12/2025 | By Akanki
CuraTeQ Biologics Receives UK MHRA Approval for Trastuzumab Biosimilar Dazublys
CuraTeQ Biologics, a wholly owned step-down subsidiary of Aurobindo Pharma, has obtained marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar, Dazublys.
Gastric Cancer | 26/08/2025 | By Dineshwori | 140
AstraZeneca's Imfinzi Granted Priority Review by FDA for Early-Stage Gastric and GEJ Cancers
The US Food and Drug Administration (FDA) has accepted AstraZeneca’s supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) and granted Priority Review for the treatment of patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.
Gastric Cancer | 28/07/2025 | By Dineshwori | 130
RedHill Biopharma Announces Roll Out of Talicia in UAE
The commercial launch of Talicia in the UAE triggers RedHill's eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales.
Gastric Cancer | 23/08/2024 | By Aishwarya | 723
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy